<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/css" href="/genius-cms/site/internal/rss/style.css" ?>

<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>

<title>Drug Discovery World</title>
<link>http://ddw-online.com/</link>
<description><![CDATA[]]></description>
<lastBuildDate>Mon, 9 Jul 2010 00:00 +0000 GMT</lastBuildDate>
<atom:link href="http://ddw-online.com/feed.rss" rel="self" type="application/rss+xml" />
<language>en</language>

<item>
<title><![CDATA[ Winter 2002 | The new BLOCKBUSTERS healthcare packages for particular disease pathologies ]]></title>
<link>http://ddw-online.com/s/winter-2002/p148514/the-new-blockbusters-healthcare-packages-for-particular-disease-pathologies.html</link>
<guid>http://ddw-online.com/s/winter-2002/p148514/the-new-blockbusters-healthcare-packages-for-particular-disease-pathologies.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ With the cost of bringing a new drug to market now exceeding $800 million there is no doubt that the pharmaceutical industry has to fundamentally address the way in which it operates.This article offers a vision of change that could alter the entire economic foundation on which Pharma functions. ]]></description>
</item>
<item>
<title><![CDATA[ Winter 2002 | stem cell PHARMACEUTICS ]]></title>
<link>http://ddw-online.com/s/winter-2002/p148513/stem-cell-pharmaceutics.html</link>
<guid>http://ddw-online.com/s/winter-2002/p148513/stem-cell-pharmaceutics.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ Recent research advances in the understanding of stem cell properties are inevitably leading to therapeutic strategies potentially applicable to many diseases.The pharmaceutical manipulation of multipotential cells such as stem cells is therefore now primed to evolve in its own right.This article focuses on known effects of introduced biologics and small molecules, and on the future of strategies enhancing the ex vivo or in vivo regenerative properties of these remarkable cells. ]]></description>
</item>
<item>
<title><![CDATA[ Winter 2002 | Second-generation protein drugs children of the revolution ]]></title>
<link>http://ddw-online.com/s/winter-2002/p148512/second-generation-protein-drugs-children-of-the-revolution.html</link>
<guid>http://ddw-online.com/s/winter-2002/p148512/second-generation-protein-drugs-children-of-the-revolution.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ The first biotech revolution was catalysed in the late 1970s with the development of recombinant DNA technology.This revolution generated numerous billion-dollar protein drugs such as erythropoietin and the interferons. Now that the patents on these drugs are expiring, will secondgeneration proteins, the children of the biotech revolution, dominate the protein drug market? ]]></description>
</item>
<item>
<title><![CDATA[ Winter 2002 | Finding and minding R&D talent the hidden human cost of merger mania ]]></title>
<link>http://ddw-online.com/s/winter-2002/p148511/finding-and-minding-r&d-talent-the-hidden-human-cost-of-merger-mania.html</link>
<guid>http://ddw-online.com/s/winter-2002/p148511/finding-and-minding-r&d-talent-the-hidden-human-cost-of-merger-mania.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ This article examines the impact on R&D staff of the current economic uncertainty, the raft of mega-mergers and the growth of the biotech sector. Senior management repeatedly comment that finding, motivating and retaining talented individuals are some of their key challenges. High calibre individuals can significantly impact the success or otherwise of a programme. ]]></description>
</item>
<item>
<title><![CDATA[ Winter 2002 | Protein arrays for assessment of target selectivity transforming knowledge of the human genome into a lead optimisation tool ]]></title>
<link>http://ddw-online.com/s/winter-2002/p148510/protein-arrays-for-assessment-of-target-selectivity-transforming-knowledge-of-the-human-genome-into-a-lead-optimisation-tool.html</link>
<guid>http://ddw-online.com/s/winter-2002/p148510/protein-arrays-for-assessment-of-target-selectivity-transforming-knowledge-of-the-human-genome-into-a-lead-optimisation-tool.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ Genomics activity has been criticised for having elucidated a plethora of potentially interesting drug targets, each awaiting further validation, but having not yet revolutionised the pharmaceutical industry or replaced traditional drug discovery pipelines. Here, we detail applications for improving target selectivity of known therapeutic molecules to known targets by employing technologies not previously accessible to the pharmaceutical industry, ie appropriatelydesigned protein biochips. Protein micro-arrays can be used to screen lead molecules (antibodies, protein biomolecules and small molecule drugs), and iterations thereof, for the most specific target binders prior to toxicological, pre-clinical and clinical testing. Improvements in target selectivity linked to optimised recognition profiles following exposure to millions of potential binding sites derived from the human genome should translate into reduced adverse drug effects and shorter times to registration. ]]></description>
</item>
<item>
<title><![CDATA[ Summer 2001 | Unrealised wealth in the avalanche of science ]]></title>
<link>http://ddw-online.com/s/summer-2001/p148574/unrealised-wealth-in-the-avalanche-of-science.html</link>
<guid>http://ddw-online.com/s/summer-2001/p148574/unrealised-wealth-in-the-avalanche-of-science.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ The human genome information complemented with high throughput screening, proteomics and molecular structure analysis has significantly increased the speed at which potential drug leads are identified. The Pandora’s box of intellectual properties opened as a result is beyond any one company’s capability to fully develop. Given the escalating cost of pharmaceutical R&D, increased productivity and return from pharmaceutical assets is critical. A key success factor for any company in life sciences is to balance internal drug development effort with active licensing activities to fully derive value of drug leads generated as a result of the avalanche of science. ]]></description>
</item>
<item>
<title><![CDATA[ Summer 2001 | Surrogate endpoints IN CANCER TRIALS ]]></title>
<link>http://ddw-online.com/s/summer-2001/p148573/surrogate-endpoints-in-cancer-trials.html</link>
<guid>http://ddw-online.com/s/summer-2001/p148573/surrogate-endpoints-in-cancer-trials.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ Over the next 20 years systematic programmes of cancer risk assessment will be established and cancer-preventive drugs will be developed. The ability to prevent cancer will dramatically increase the number of people who will need to regularly attend clinics. This article discusses how we urgently need surrogate endpoints to enhance the speed of assessment in the development of drugs in this presently under-researched area and the potential benefits they can bring such as lowering costs, reducing time to NDA, bypassing need for phase II studies and reviving dead drugs. ]]></description>
</item>
<item>
<title><![CDATA[ Summer 2001 | STEM CELLS the long march forward to the clinic ]]></title>
<link>http://ddw-online.com/s/summer-2001/p148572/stem-cells-the-long-march-forward-to-the-clinic.html</link>
<guid>http://ddw-online.com/s/summer-2001/p148572/stem-cells-the-long-march-forward-to-the-clinic.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ The area of cellular therapeutics has never been readily embraced by ‘Big Pharma’, with ethical and regulatory issues even more complex and troublesome than proteins. Can stem cell therapy provide the key to unlocking a rich vein of pharmaceutical activity? ]]></description>
</item>
<item>
<title><![CDATA[ Summer 2001 | PROTEIN ARRAYS new technology for the proteomics era ]]></title>
<link>http://ddw-online.com/s/summer-2001/p148571/protein-arrays-new-technology-for-the-proteomics-era.html</link>
<guid>http://ddw-online.com/s/summer-2001/p148571/protein-arrays-new-technology-for-the-proteomics-era.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ The study of the human proteome will drive drug discovery in coming years; although how, when, and in what direction are a little uncertain at present. To build understanding of the role of the human protein complement in health, development, and disease, a database more complex than the human genetic sequence is under construction. To face the challenge, new technologies for protein analysis must be developed that are faster and provide more information than current approaches. ]]></description>
</item>
<item>
<title><![CDATA[ Summer 2001 | PHARMACOGENETICS a review of concepts and contents ]]></title>
<link>http://ddw-online.com/s/summer-2001/p148570/pharmacogenetics-a-review-of-concepts-and-contents.html</link>
<guid>http://ddw-online.com/s/summer-2001/p148570/pharmacogenetics-a-review-of-concepts-and-contents.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ Pharmacogenetics represents a logical and consequent step in the history of medicine, but what are the immediate benefits and where do the hurdles lie in its implementation? ]]></description>
</item>
<item>
<title><![CDATA[ Spring 2001 | REGENERATIVE MEDICINE promising answers in the face of an ageing population ]]></title>
<link>http://ddw-online.com/s/spring-2001/p148582/regenerative-medicine-promising-answers-in-the-face-of-an-ageing-population.html</link>
<guid>http://ddw-online.com/s/spring-2001/p148582/regenerative-medicine-promising-answers-in-the-face-of-an-ageing-population.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ As the population ages, the scientific and medical communities are working to solve the challenges this changing demographic will place on society. Companies involved in the promising field of regenerative medicine are now on the cutting edge as it strives to promote longevity without disability. ]]></description>
</item>
<item>
<title><![CDATA[ Spring 2001 | Protein therapeutics – new ladders up the fruit tree ]]></title>
<link>http://ddw-online.com/s/spring-2001/p148581/protein-therapeutics-–-new-ladders-up-the-fruit-tree.html</link>
<guid>http://ddw-online.com/s/spring-2001/p148581/protein-therapeutics-–-new-ladders-up-the-fruit-tree.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ Therapeutic proteins are often regarded as too technologically demanding, too costly, too restricted in routes or duration of administration or – in an era of massive opportunity provided by high throughput screening, combinatorial chemistry and genomics – simply passé. This article explores how fundamental advances (such as definition of the human proteome and protein combinatorics) as well as incremental steps forward (such as improvements in production methods) are rapidly expanding therapeutic uses for the biology’s most important molecules. ]]></description>
</item>
<item>
<title><![CDATA[ Spring 2001 | Pharmaceutical industry R&D partnering strategies ]]></title>
<link>http://ddw-online.com/s/spring-2001/p148580/pharmaceutical-industry-r&d-partnering-strategies.html</link>
<guid>http://ddw-online.com/s/spring-2001/p148580/pharmaceutical-industry-r&d-partnering-strategies.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ With a sustained rate of more than 250 R&D partnering deals each year many valuable lessons are being learned. Although there is no exact ‘formula for success’ there are many ‘success factors’ that can be utilised to reduce the risk of failure. ]]></description>
</item>
<item>
<title><![CDATA[ Spring 2001 | Modelling and simulation in drug development, promise and reality ]]></title>
<link>http://ddw-online.com/s/spring-2001/p148579/modelling-and-simulation-in-drug-developmentpromise-and-reality.html</link>
<guid>http://ddw-online.com/s/spring-2001/p148579/modelling-and-simulation-in-drug-developmentpromise-and-reality.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ Modelling and simulation in drug development is not new. What is new is the<br>vision for moving from a descriptive role (what happened) to a predictive and<br>therefore decision making role. While seemingly attractive, important hurdles,<br>both scientific and practical, must be overcome. ]]></description>
</item>
<item>
<title><![CDATA[ Spring 2001 | Increasing the chances of lead discovery ]]></title>
<link>http://ddw-online.com/s/spring-2001/p148578/increasing-the-chances-of-lead-discovery.html</link>
<guid>http://ddw-online.com/s/spring-2001/p148578/increasing-the-chances-of-lead-discovery.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ For HTS laboratories worldwide, the mission is to supply therapeutic groups – in the shortest time possible – with high quality hits and leads that will become drug candidates. Mounting pressure to screen more targets against more compounds while providing more information per screen has HTS directors seeking improvements to existing technologies as well as innovative new approaches and tools. ]]></description>
</item>
<item>
<title><![CDATA[ Winter 2001 | TOXICOGENOMICS insights into the present and future ]]></title>
<link>http://ddw-online.com/s/winter-2001/p148590/toxicogenomics-insights-into-the-present-and-future.html</link>
<guid>http://ddw-online.com/s/winter-2001/p148590/toxicogenomics-insights-into-the-present-and-future.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ Adverse drug responses are an important post-marketing public health issue, occurring many times in subsets of treatment populations. Promising new approaches to predicting physiological responses to drugs are focused on ‘genomic responses’ or toxicogenomics1. This article provides a current perspective on toxicogenomics technologies that are aimed at: 1) providing new tools and systems for more rapid, accurate and complete toxicity assessments in advance of human exposure; 2) enhancing the thoroughness and accuracy of toxicity assessments achievable with currently available test systems, and 3) predictive assessments of individualised risk for developing adverse drug reactions. ]]></description>
</item>
<item>
<title><![CDATA[ Winter 2001 | METABOLISM provides alternative door to stroke therapy ]]></title>
<link>http://ddw-online.com/s/winter-2001/p148589/metabolism-provides-alternative-door-to-stroke-therapy.html</link>
<guid>http://ddw-online.com/s/winter-2001/p148589/metabolism-provides-alternative-door-to-stroke-therapy.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ Even in the age of genomics and gene hunters, a holistic view of cell metabolism can result in revolutionary new drugs. ]]></description>
</item>
<item>
<title><![CDATA[ Winter 2001 | SILICON TECHNOLOGY AND PHARMACEUTICS – an impending marriage in the nanoworld ]]></title>
<link>http://ddw-online.com/s/winter-2001/p148588/silicon-technology-and-pharmaceutics-–-an-impending-marriage-in-the-nanoworld.html</link>
<guid>http://ddw-online.com/s/winter-2001/p148588/silicon-technology-and-pharmaceutics-–-an-impending-marriage-in-the-nanoworld.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ The recent discovery that, following nanostructuring, silicon can be rendered biocompatible and biodegradable has far reaching and profound long-term implications for the pharmaceutical industry and, indeed, medicine as a whole. ]]></description>
</item>
<item>
<title><![CDATA[ Winter 2001 | PROTEOMICS IN DRUG TARGET DISCOVERY – High-throughput meets high-efficiency ]]></title>
<link>http://ddw-online.com/s/winter-2001/p148587/proteomics-in-drug-target-discovery-–-high-throughput-meets-high-efficiency.html</link>
<guid>http://ddw-online.com/s/winter-2001/p148587/proteomics-in-drug-target-discovery-–-high-throughput-meets-high-efficiency.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ Biochemistry is enjoying a renaissance under the guise of ‘proteomics’ due to the availability of sequenced genomes, advances in mass spectrometry and associated data analysis. Its application to drug discovery and development has obvious benefits to the multiple aspects of drug development but this is only beginning to be realised. This article explores the emerging technologies of non-gel based methods for protein quantitation and identification together with the trend towards focused studies rather than global approaches to protein expression level analyses. ]]></description>
</item>
<item>
<title><![CDATA[ Winter 2001 | A revolution in R&D – the managerial challenges ]]></title>
<link>http://ddw-online.com/s/winter-2001/p148586/a-revolution-in-r&d-–-the-managerial-challenges.html</link>
<guid>http://ddw-online.com/s/winter-2001/p148586/a-revolution-in-r&d-–-the-managerial-challenges.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ The genomics revolution is poised to sweep aside the old economics of pharmaceutical R&D. The biotechnology and pharmaceutical industries – and perhaps healthcare delivery in general – are on the brink of transformation, and companies that embrace the revolution in the right way stand to reap enormous benefits. Developing a new drug should become considerably less unpredictable and much less expensive. Companies will record improvements both in efficiency and in success rates all along the value chain, and the average cost and time needed to bring a new drug to market will fall correspondingly. But this benign prospect is clouded by some warnings: great rewards will require comparably great efforts; a new paradigm in R&D economics may necessitate paradigm shifts in R&D management; above all, the great promise is offset by great risks – though, as in any revolution, the risks of standing aside may be greater than those of getting involved. ]]></description>
</item>
<item>
<title><![CDATA[ Fall 2001 | Why pharmaceutical companies should teach scientists to be ENTREPRENEURS ]]></title>
<link>http://ddw-online.com/s/fall-2001/p148602/why-pharmaceutical-companies-should-teach-scientists-to-be-entrepreneurs.html</link>
<guid>http://ddw-online.com/s/fall-2001/p148602/why-pharmaceutical-companies-should-teach-scientists-to-be-entrepreneurs.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ Conventional wisdom says that big employers do not want anything to do with entrepreneurs as employees. The last thing a human resources director wants to see on a resumé is that a candidate started a business and failed. The suspicion is that these candidates are only looking for a temporary safe haven. Never mind the stigma of failure (despite what skills that may develop); this is a person who will only use your phones and computers to work on the next idea, and will jump ship at the first chance to chase the next entrepreneurial opportunity. ]]></description>
</item>
<item>
<title><![CDATA[ Fall 2001 | The ‘lab on a chip’ and its impact on drug discovery ]]></title>
<link>http://ddw-online.com/s/fall-2001/p148601/the-‘lab-on-a-chip’-and-its-impact-on-drug-discovery.html</link>
<guid>http://ddw-online.com/s/fall-2001/p148601/the-‘lab-on-a-chip’-and-its-impact-on-drug-discovery.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ Few technology developments have had as profound an effect on society as the invention of the microchip integrated circuit in the 1960s. Since then, the power of electronic circuits has increased while their cost in real terms has dropped, and both by similar proportions. The evolution of microprocessors gives an excellent illustration of this with Moore’s law1 providing a prediction which has proved remarkably accurate to date. In fact, information technology is the key area to which microchip technology has been applied, and its influence has been immense, not least on science. Miniaturisation has gone hand-in-hand with this, and it is now one of the most important technology developments of our times. Most visible in electronics, computing and telecommunications, miniaturisation has revolutionised everyday life, and personal computers and telephones, whose power is vast compared to their 1970s counterparts, are now household items. ]]></description>
</item>
<item>
<title><![CDATA[ Fall 2001 | How drug regulatory authorities are adapting to new technologies ]]></title>
<link>http://ddw-online.com/s/fall-2001/p148600/how-drug-regulatory-authorities-are-adapting-to-new-technologies.html</link>
<guid>http://ddw-online.com/s/fall-2001/p148600/how-drug-regulatory-authorities-are-adapting-to-new-technologies.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ The past few years have seen the emergence of a number of new technologies. Some of these advances will have a significant effect on the nature of medicines and the way in which they are developed. This article discusses some of the significant changes in the regulatory oversight of drug development and licensing. ]]></description>
</item>
<item>
<title><![CDATA[ Fall 2001 | Evaluating future drug candidates and their manufacture together ]]></title>
<link>http://ddw-online.com/s/fall-2001/p148599/evaluating-future-drug-candidates-and-their-manufacture-together.html</link>
<guid>http://ddw-online.com/s/fall-2001/p148599/evaluating-future-drug-candidates-and-their-manufacture-together.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ Classically, evaluating a candidate drug has preceded evaluation of the process for making it. The late rush to process development worked reasonably well with simple chemical pharmaceuticals. With complex biopharmaceuticals, a new approach is needed. One now being developed has implications for increasingly complex small molecule pharmaceuticals and can cut time, costs and risk. ]]></description>
</item>
<item>
<title><![CDATA[ Fall 2001 | DATA MINING in the pharmaceutical industry ]]></title>
<link>http://ddw-online.com/s/fall-2001/p148598/data-mining-in-the-pharmaceutical-industry.html</link>
<guid>http://ddw-online.com/s/fall-2001/p148598/data-mining-in-the-pharmaceutical-industry.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ A research-based pharmaceutical company is a data accumulating wonder. More than in any other industry, success is predicated on the collection, processing and exploitation of that data. This is not always recognised and often not planned for by large pharmaceutical companies. Now, however, with the advent of data storage and mining techniques making major advances in other industries, the pharmaceutical industry must adjust to fully exploit this potential competitive advantage in discovery, development and marketing of their products. We discuss some of the impacts to companies and some of the adjustments they will have to make to maintain their position in the information age. ]]></description>
</item>
<item>
<title><![CDATA[ Winter 2000 | Putting the code to work: the promise of pharmacogenetics and pharmacogenomics ]]></title>
<link>http://ddw-online.com/s/winter-2000/p148609/putting-the-code-to-work:-the-promise-of-pharmacogenetics-and-pharmacogenomics.html</link>
<guid>http://ddw-online.com/s/winter-2000/p148609/putting-the-code-to-work:-the-promise-of-pharmacogenetics-and-pharmacogenomics.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ Within the next 10 years the benefits of pharmacogenetics and pharmacogenomics will inevitably outweigh the disadvantages. But what are the commercial and legal implications for the pharmaceutical industry especially for companies who have lead candidates ready to enter development? ]]></description>
</item>
<item>
<title><![CDATA[ Winter 2000 | HTS where next? ]]></title>
<link>http://ddw-online.com/s/winter-2000/p148608/hts-where-next.html</link>
<guid>http://ddw-online.com/s/winter-2000/p148608/hts-where-next.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ After approximately a decade of maturation and a three orders of magnitude increase in capabilities, High Throughput Screening (HTS) is now an established discipline within pharmaceutical discovery. But opposing stresses exist within the screening world – the resolution of which will significantly affect the path along which the HTS discipline will develop. ]]></description>
</item>
<item>
<title><![CDATA[ Winter 2000 | Do venture capitalists act as gatekeepers of new technology? ]]></title>
<link>http://ddw-online.com/s/winter-2000/p148607/do-venture-capitalists-act-as-gatekeepers-of-new-technology.html</link>
<guid>http://ddw-online.com/s/winter-2000/p148607/do-venture-capitalists-act-as-gatekeepers-of-new-technology.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ article discusses the important role that venture capitalists and others play in helping to create companies around new technologies. We asked a number of venture capitalists, when considering funding a new company, what was most important to them – people or science. We also asked whether they knew of technology that, without their sponsorship wouldn’t have been exploited. ]]></description>
</item>
<item>
<title><![CDATA[ Winter 2000 | The genie in the test tube – from gene to gene therapy: part II ]]></title>
<link>http://ddw-online.com/s/winter-2000/p148606/the-genie-in-the-test-tube-–-from-gene-to-gene-therapy:-part-ii.html</link>
<guid>http://ddw-online.com/s/winter-2000/p148606/the-genie-in-the-test-tube-–-from-gene-to-gene-therapy:-part-ii.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ In the previous edition, we discussed gene therapy in terms of potential vectors and their applications. Now, we discuss the potential clinical uses of these constructs. To date, the main applications of gene therapy have been in inborn errors of metabolism, cancer, cardiovascular and central nervous system degenerative disease and transplantation and graft versus host disease. However, it would seem that this list is set to grow as understanding of the fundamental causes of disease and of delivery mechanisms for gene therapy become better understood. ]]></description>
</item>
<item>
<title><![CDATA[ Winter 2000 | High-throughput CRYSTALLISATION ]]></title>
<link>http://ddw-online.com/s/winter-2000/p148605/high-throughput-crystallisation.html</link>
<guid>http://ddw-online.com/s/winter-2000/p148605/high-throughput-crystallisation.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ With structure-based drug design on the increase can the development of high-throughput crystallisation fulfil its promise to revolutionise the drug discovery process? ]]></description>
</item>
<item>
<title><![CDATA[ Summer 2000 | using expression databases for drug discovery ]]></title>
<link>http://ddw-online.com/s/summer-2000/p148622/using-expression-databases-for-drug-discovery.html</link>
<guid>http://ddw-online.com/s/summer-2000/p148622/using-expression-databases-for-drug-discovery.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ Reference databases are being built cataloguing the amount of RNA each gene makes under different conditions and in different individuals. These databases can be mined easily and effectively to aid the drug discovery process. ]]></description>
</item>
<item>
<title><![CDATA[ Summer 2000 | introduction ]]></title>
<link>http://ddw-online.com/s/summer-2000/p148621/introduction.html</link>
<guid>http://ddw-online.com/s/summer-2000/p148621/introduction.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[  ]]></description>
</item>
<item>
<title><![CDATA[ Summer 2000 | target discovery and drug design: extracting the value from genomics ]]></title>
<link>http://ddw-online.com/s/summer-2000/p148620/target-discovery-and-drug-design:-extracting-the-value-from-genomics.html</link>
<guid>http://ddw-online.com/s/summer-2000/p148620/target-discovery-and-drug-design:-extracting-the-value-from-genomics.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ Pharmaceutical research and development is changing. The old model of drug discovery, based on a combination of imprecise candidate generation and broad physiological screens, has given way to more specific and intelligent approaches to target identification and drug design. Now, a vast influx of genomic information is set to revolutionise the range of targets available, at least to those able to navigate effectively through the bewildering immensity of the world’s genomic data archives. ]]></description>
</item>
<item>
<title><![CDATA[ Summer 2000 | plants as a source of new medicines ]]></title>
<link>http://ddw-online.com/s/summer-2000/p148619/plants-as-a-source-of-new-medicines.html</link>
<guid>http://ddw-online.com/s/summer-2000/p148619/plants-as-a-source-of-new-medicines.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ Putting aside the excitement surrounding the human genome, in the near future we may well start to see the emergence of a new class of prescription medicine containing complex mixtures of plant extracts. This article discusses the important role that plants can play in the search for new medicines and effective therapies. ]]></description>
</item>
<item>
<title><![CDATA[ Summer 2000 | HTS a strategy for drug discovery ]]></title>
<link>http://ddw-online.com/s/summer-2000/p148614/hts-a-strategy-for-drug-discovery.html</link>
<guid>http://ddw-online.com/s/summer-2000/p148614/hts-a-strategy-for-drug-discovery.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ Whichever technologies are implemented, high throughput screening is set to become one of the cornerstones of drug discovery, however deciding which strategy to implement will provide many headaches. This article concentrates on screens identifying the interaction of small molecules with protein targets rather than target identification screens. ]]></description>
</item>
<item>
<title><![CDATA[ Biomarkers | Composite Profiling of Angiogenic Factors Using Bio-Plex Human Cancer Biomarker Panel 1 ]]></title>
<link>http://ddw-online.com/s/biomarkers/p148770/composite-profiling-of-angiogenic-factors-using-bio-plex-human-cancer-biomarker-panel-1.html</link>
<guid>http://ddw-online.com/s/biomarkers/p148770/composite-profiling-of-angiogenic-factors-using-bio-plex-human-cancer-biomarker-panel-1.html</guid>
<pubDate>Mon, 9 Jul 2010 12:37:00 GMT</pubDate>
<description><![CDATA[ Angiogenesis is a fundamental process required for multiple physiological and pathological events. It is also a hallmark of over 50 different disease states, including cancer, rheumatoid arthritis, cardiovascular diseases, diabetes, and psoriassis. ]]></description>
</item>


</channel>
</rss>
